Risperidone in children with disruptive behavior disorders: A 2-year open-label trial

被引：0
|
作者：
Reyes-Harde, M
Croonenberghs, J
Eerdekens, M
机构：
[1] Univ Antwerp, AZ Middelheim, Ctr Child & Adolescent Psychiat, B-2020 Antwerp, Belgium
[2] Johnson & Johnson Pharmaceut Res & Dev, Beerse, Belgium
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2004年 / 14卷
关键词：
D O I：
10.1016/S0924-977X(04)80315-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S274 / S274
页数：1
相关论文
共 50 条
  • [41] A prospective open-label long-term treatment trial of risperidone monotherapy in children and adolescents with bipolar disorder
    Biederman, J
    Mick, E
    Wozniak, J
    Harpold, T
    Aleardi, M
    Dougherty, M
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S602 - S603
  • [42] Long-term safety and efficacy of risperidone in children with disruptive behaviour disordersResults of a 2-year extension study
    Magali Reyes
    Roza Olah
    Krisztina Csaba
    Ilse Augustyns
    Marielle Eerdekens
    European Child & Adolescent Psychiatry, 2006, 15 : 97 - 104
  • [43] Bumetanide for autism: Open-label trial in six children
    Fernell, Elisabeth
    Gustafsson, Peik
    Gillberg, Christopher
    ACTA PAEDIATRICA, 2021, 110 (05) : 1548 - 1553
  • [44] OPEN-LABEL TRIAL WITH VIGABATRIN IN CHILDREN WITH INTRACTABLE EPILEPSY
    WONG, V
    BRAIN & DEVELOPMENT, 1995, 17 (04): : 249 - 252
  • [45] Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior
    Buitelaar, JK
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2000, 10 (01) : 19 - 26
  • [46] Long-term efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: Results of an open-label, 2-year trial
    Haibel, H.
    Brandt, H. C.
    Baraliakos, X.
    Rudwaleit, M.
    Listing, J.
    Braun, J.
    Kupper, H.
    Sieper, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 218 - 219
  • [47] Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma A Single-Center, Open-Label, 2-Year Randomized Clinical Trial
    Batista, Rafael L.
    Musolino, Nina R. C.
    Cescato, Valter A. S.
    da Silva, Gilberto O.
    Medeiros, Raphael S. S.
    Herkenhoff, Clarissa G. B.
    Trarbach, Ericka B.
    Cunha-Neto, Malebranche B.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (02): : 221 - 227
  • [48] Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study
    Liu, Kun
    Wang, Hanying
    He, Wei
    Ye, Jian
    Song, Yanping
    Wang, Yusheng
    Liu, Xiaoling
    Wu, Zhifeng
    Chen, Shaojun
    Fan, Ke
    Liu, Yuling
    Zhang, Feng
    Li, Zhiqing
    Liu, Lin
    Zhang, Junjun
    Zhang, Xuedong
    Ye, Junjie
    Liang, Xiaoling
    Li, Xiaoxin
    Ke, Xiao
    Wu, Quan
    Li, Jie
    Tao, Shanshan
    Wang, Xinguo
    Rosenfeld, Philip
    Heier, Jeffrey S.
    Kaiser, Peter
    Xu, Xun
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2022, 106 (10) : 1436 - 1443
  • [49] Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
    Kudrow, David
    Cady, Roger K.
    Allan, Brent
    Pederson, Susan M.
    Hirman, Joe
    Mehta, Lahar R.
    Schaeffler, Barbara A.
    BMC NEUROLOGY, 2021, 21 (01)
  • [50] Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
    David Kudrow
    Roger K. Cady
    Brent Allan
    Susan M. Pederson
    Joe Hirman
    Lahar R. Mehta
    Barbara A. Schaeffler
    BMC Neurology, 21
12345